FINWIRES · TerminalLIVE
FINWIRES

IGO's Shareholder Upside Muted Despite Robust Lithium Market, Says Jefferies

By

-- IGO's (ASX:IGO) structural issues and weak performance at its key Greenbushes asset are limiting shareholder exposure to upside despite a strong lithium market, Jefferies said in a note on Monday.

The company reduced the fiscal 2026 spodumene production guidance from the Greenbushes lithium mine in Western Australia to 1.38 million tonnes to 1.43 million tonnes, reflecting performance year-to-date and CGP3 ramp-up expectations for the June quarter. Jefferies had expected Greenbushes 2026 production of 1.5 million tonnes.

It also lowered capital expenditure outlook for the operation to AU$400 million to AU$450 million from AU$575 million to AU$675 million, compared with Jefferies' projection of AU$565 million.

The company's Kwinana asset remains economically challenged and a large shutdown in April and May is to impact its June quarter output, the investment firm added.

Jefferies reaffirmed a hold rating on IGO and cut its price target to AU$7 from AU$8.

Related Articles

International

Japan's Unemployment Rate Ticks Up to 2.7% in March

Japan's unemployment rate inched up to 2.7% in March compared with the previous month's 2.6%, according to government data released on Tuesday.The data showed that the number of employed decreased slightly to a seasonally adjusted 68.15 million from 68.27 million in February, while the number of jobless people increased to 1.86 million from 1.85 million the prior month.

$^N225
Asia

Market Chatter: Japan Faces Risk of Missing on New Drugs Due to US Pricing Model

Japan may miss out on breakthrough drugs because a U.S. pricing model threatens to link American drug costs to lower Japanese prices under the most favored nation (MFN) plan, Nikkei reported on Tuesday.Under the plan, the U.S. would reference prices from countries, including Japan, for Medicare and Medicaid, though companies could avoid this by not launching products in Japan, the news daily said.This could lead pharmaceutical firms to delay or skip entering the Japanese market, while Japan might face upward pressure on drug prices and higher social insurance costs, the publication said.Industry groups are urging Japan to reassess its pricing rules to align innovative drug prices with international levels and maintain them during patent periods, the report said.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

$^N225
Asia

Echo IQ Deploys AI-Based Decision Support Software into the US Health System

Echo IQ (ASX:EIQ) deployed EchoSolv AS, its artificial intelligence-based decision support software for the assessment of severe aortic stenosis, into the Mount Sinai Health System in New York, according to a Tuesday filing with the Australian bourse.The company continues to engage with prospective hospitals in the US regarding potential opportunities for the product, the filing said.

$ASX:EIQ